ORM-6151

BMS Acquires Orum's ADC ORM-6151 for AML and MDS Treatment

BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment

Anika Sharma

Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...